Summary
2% amphotericin B in orabase® was applied to the buccal mucous membranes of healthy volunteers. Amounts of 1 g and 0.5 g were used. The experiments were performed during the day time as well as during the sleeping hours at night. At several intervals after application saliva samples were collected and the amphotericin B concentrations were determined. Application of 1 g of orabase® with 2% amphotericin B appears to maintain a sufficiently high concentration for four hours, 0.5 g for three hours. Application of these amounts before going to sleep guarantees a sufficient concentration until awakening the next morning.
Zusammenfassung
2% Amphotericin-B im Orabase wurde auf die Rachenschleimhaut gesunder Freiwilliger appliziert. Dabei kamen Mengen von 1 g bzw. 0,5 g zur Anwendung. Die Experimente wurden während des Tages und während der Nacht durchgeführt. Mehrmals nach der Anwendung wurden Speichelproben gesammelt und die Amphotericin-B-Konzentrationen bestimmt. Die Applikation von 1 g der Orabase von 2% Amphotericin-B scheint eine ausreichend hohe Antibiotika-Konzentration für vier Stunden zu geben, 0,5 g für drei Stunden. Die Anwendung dieser Mengen vor dem Schlafengehen garantiert eine ausreichende Konzentration bis zum nächsten Morgen.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Literature
Armstrong, D. Infectious complications in cancer patients treated with chemical immunosuppressive agents. Symposium on human aspects of clinical transplantation, San Francisco 1972. Transplantation Proceedings, Vol. V, No. 3. (1973) 1245–1248.
Schimpff, S. C., Young, V. M., Greene, W. H., Vermeulen, G. D., Moody, M. R., Wiernik, P. H. Origin of infection in acute nonlymphocytic leukemia. Significance of hospital acquisition of potential pathogens. Ann. Intern. Med. 77 (1972) 707–714.
Burgess, M. A., Gruchy, G. C. de Septicaemia in acute leukaemia. Med. J. Aust. 22 (1969) 1113–1117.
Dietrich, M., Gaus, W., Vossen, J., Waaij, D. van der, Wendt, F. Protective isolation and antimicrobial decontamination in patients with high susceptibility to infection: a prospective cooperative study of gnotobiotic care in acute leukemia patients. Part I: Clinical results. Infection 5 (1977) 107–114.
Loesche, W. J., Nafe, D. Reduction of supregingival plague accumulations in institutionalized Down's syndrome patients by periodic treatment with topical kanamycin. Arch. Oral Biol. 18 (1973) 1131–1143.
Dobias, B., Hazen, E. L. Nystatin. Chemotherapia 3 (1961) 108–119.
Walter, A. M., Heilmeyer, L. (Ed.): Antibiotika-Fibel, p. 666–701. Georg Thieme Verlag, Stuttgart 1975.
Goss, W. A., Cimijotti, B.: Evaluation of an automatic diluting device for microbiological applications. Appl. Microbiol. (1968) 1414–1416.
Thomas, A. H. Analysis and assay of polyene antifungal antibiotics. Analyst 101 (1976) 321–340.
Waaij, D. van der, Vossen, J. Antibiotic decontamination in animals and human patients. Proc. 1st Intersectional Congress International Association of Microbiological Societies p. 233–249. Science Council of Japan, Tokyo 1975.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
de Vries-Hospers, H.G., van der Waaij, D. Amphotericin B concentrations in saliva after application of 2% amphotericin B in orabase®. Infection 6, 16–20 (1978). https://doi.org/10.1007/BF01641085
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF01641085